NCT06672159 Initial Double Sequential External Defibrillation in Out of Hospital Cardiac Arrest
| NCT ID | NCT06672159 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Olavs Hospital |
| Condition | Cardiac Arrest |
| Study Type | INTERVENTIONAL |
| Enrollment | 356 participants |
| Start Date | 2025-04-28 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 356 participants in total. It began in 2025-04-28 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Double Sequential External Defibrillation (DSED) represents an alternative treatment of refractory ventricular fibrillation (rVF) in out-of-hospital cardiac arrest (OHCA). The procedure consists of two defibrillators that administer shocks at the same time. Currently, the procedure is not initiated before at least three failed attempts with one defibrillator. This can delay the potential benefits of establishing DSED earlier in the treatment. Studies have shown that early defibrillation is crucial for survival in OHCA patients, and in 2022, a clinical trial showed that survival in patients treated with DSED was higher compared to standard treatment. The effect of initiating OHCA treatment is unknown. The DUALDEFIB trial seeks to investigate if treating OHCA patients with DSED as an initial treatment will increase survival and provide improved neurological outcome.
Eligibility Criteria
Inclusion Criteria: * Patients with out of hospital cardiac arrest presenting with a shockable rhythm Exclusion Criteria: * Age below 18 years * Obvious or suspected pregnancy * Incarcerated patients * Preexisting do-not-resuscitate order
Contact & Investigator
Kjetil Karlsen
STUDY DIRECTOR
St. Olavs Hospital
Frequently Asked Questions
Who can join the NCT06672159 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Arrest. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06672159 currently recruiting?
Yes, NCT06672159 is actively recruiting participants. Contact the research team at jostein.brede@norskluftambulanse.no for enrollment information.
Where is the NCT06672159 trial being conducted?
This trial is being conducted at Trondheim, Norway.
Who is sponsoring the NCT06672159 clinical trial?
NCT06672159 is sponsored by St. Olavs Hospital. The principal investigator is Kjetil Karlsen at St. Olavs Hospital. The trial plans to enroll 356 participants.